Accupril (Quinapril HCl Tablets) 10 mg, 90 Tablets Rx only NDC 0071-0530-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017
Published May 25, 2022 · Recall initiated: April 22, 2022
Summary
FDA records drug Class II recall D-0872-2022, published May 25, 2022 and initiated April 22, 2022. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 2079 bottles; Lot: Lot: DR9639 Exp. MAR 31 2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
What to do
Voluntary: Firm initiated · Press Release
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Pfizer Inc.
- Distributor
- Nationwide and Puerto Rico
- Lot
- Lot: DR9639 Exp. MAR 31 2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units per 4 mL, 4ml-vial, Rx Only,August 6, 2025
- FDABicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only,August 6, 2025
- FDADOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials,July 2, 2025
- FDALabetalol Hydrochloride Injection, USP, 20 mg/4 mL (5 mg/mL), 4 mL Single-dose Carpuject, Sterile CartridgeJuly 3, 2024
- FDAMagnesium Hydroxide 1200mg, Aluminum Hydroxide 1200mg, Simethicone 120mg, 30 mL cup, packaged in 10 cups perMay 25, 2022
- FDAAccupril (Quinapril HCl Tablets) 20 mg, 90 Tablets, Rx only NDC 0071-0532-23 Distributed by: Parke-DavisMay 25, 2022
Questions about this recall
Was Accupril (Quinapril HCl Tablets) 10 mg, 90 Tablets Rx only NDC 0071-0530-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017 recalled?
Yes. FDA published recall D-0872-2022 on May 25, 2022. Reported hazard: CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
What should I do if I have this product?
Voluntary: Firm initiated · Press Release